• Orion Animal Health won US Food and Drug Administration clearance on May 6, 2026 for Tessie (tasipimidine oral solution) to treat noise aversion and separation anxiety in dogs.
• Zoetis holds exclusive rights to market and sell Tessie in US, with launch expected by mid-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orion Oyj published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605120330OMX_____CNEWS_FI_GNW1001181411_fi) on May 12, 2026, and is solely responsible for the information contained therein.